Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Status:
Not yet recruiting
Trial end date:
2023-12-20
Target enrollment:
Participant gender:
Summary
Due to the biological characteristics and liver anatomical characteristics of liver cancer,
liver cancer cells easily invade the vascular system, especially the portal venous system,
forming portal vein tumor thrombus (PVTT) , and its incidence is reported to be 44.0% ~
62.2%. Once PVTT occurs in patients with liver cancer, the disease develops rapidly, and
intrahepatic and extrahepatic metastasis, portal hypertension, jaundice, and abdominal
effusion can occur in a short time with an average survival time of 2.7 months. PVTT is one
of the major adverse factors for the prognosis of liver cancer and occupies an important
weight influence in the clinical staging system of liver cancer. In some hepatocellular
carcinoma (HCC) patients with PVTT and selective resectability, surgery versus non-surgery
can lead to better survival of patients.
A retrospective analysis showed that neoadjuvant radiotherapy can reduce the extent of
invasion of PVTT and improve postoperative survival in some HCC patients. Another prospective
study showed that neoadjuvant radiotherapy could significantly improve the overall survival
of resectable liver cancer with PVTT, and neoadjuvant radiotherapy could improve the 2-year
survival of patients from 9.4% to 27.4% 27.4%, with an effective response of 20.7%.
This study is a prospective, single-center, single-arm study to assess the efficacy and
safety of neoadjuvant therapy with tislelizumab combined with IMRT for resectable liver
cancer with PVTT.